Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s
cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most
pressing challenges in cancer care.

Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most pressing challenges in cancer care.

Download full pipeline
Area of interest
Area of interest
Planned
Ongoing
Completed

Filters

Filter
Development phase
Phase 1
Phase 2
Phase 3
Molecule
BG-68501
BG-C137
BG-C477
BG-C9074
BG-T187
BGB-15025
BGB-16673
BGB-21447
BGB-24714
BGB-26808
BGB-30813
BGB-43395
BGB-45035
BGB-53038
BGB-58067
BGB-A3055
BGB-A317
BGB-A445
BGB-B2033
BGB-B3227
BGB-C354
BGB-R046
Blinatumomab
LBL-007
Pamiparib
Sonrotoclax
Tarlatamab
Tislelizumab
Umbrella
Xaluritamig
Zanidatamab
Zanubrutinib
Compound type
ADC
Bi/Tri-specific
Cytokine therapy
mAb
Protein degrader
Small molecule

1Amgen collaboration; BeiGene has China commercial rights. 2Ensem collaboration; BeiGene has global rights. 3DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 4Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 5Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 6Amgen collaboration; BeiGene has development and commercialization rights in China. 7Amgen collaboration; BeiGene has development and commercialization rights in China. aIn combination with Zanubrutinib. bMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. * Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.